야누스 키나아제 3을 활성을 선택적으로 저해하는 플라보노이드 유도체
    5.
    发明公开
    야누스 키나아제 3을 활성을 선택적으로 저해하는 플라보노이드 유도체 有权
    FLAVONOID衍生物选择性抑制JANUS KINASE 3的活性

    公开(公告)号:KR1020140033643A

    公开(公告)日:2014-03-19

    申请号:KR1020120099715

    申请日:2012-09-10

    Inventor: 정유훈 김미경

    Abstract: The present invention relates to flavonoid derivatives selectively inhibiting an activity of janus kinase 3, a method for manufacturing the same, and a use of the compound as immunosuppressive agents. The compound can be used as a safe immunosuppressive agent since the compound does not cause problems like pernicious anemia which is a side effect of a conventional immunosuppressant using JAK3 inhibitors.

    Abstract translation: 本发明涉及选择性抑制琼斯激酶3活性的类黄酮衍生物,其制备方法,以及该化合物作为免疫抑制剂的用途。 该化合物可以用作安全的免疫抑制剂,因为该化合物不引起诸如使用JAK3抑制剂的常规免疫抑制剂的副作用的恶性贫血等问题。

    아릴 디케토산(ADK) 유도체를 유효성분으로 포함하는 사스 코로나 바이러스 저해용 조성물
    7.
    发明公开
    아릴 디케토산(ADK) 유도체를 유효성분으로 포함하는 사스 코로나 바이러스 저해용 조성물 失效
    用于抑制包含ARYL DIKETOACID衍生物的SARS COR IR ES ES ES ES ES ES ES ES

    公开(公告)号:KR1020100029528A

    公开(公告)日:2010-03-17

    申请号:KR1020080088348

    申请日:2008-09-08

    Abstract: PURPOSE: A SARS coronavirus helicase and/or composition for suppressing SARS coronavirus helicase containing aryl diketoacid(ADK) are/is provided to suppress DNA double strand unwinding of SARS coronavirus helicase. CONSTITUTION: An inhibitor of DNA double strand unwinding of SARS coronavirus helicase contains a compound of chemical formula 1 and its pharmaceutically acceptable salt. In chemical formula 1, R1 is hydrogen, R2-R5 are independently hydrogen, or R6-(CH2)n-R7, R6 is O or NH, n IS 1-3 integer, and R7 is phenyl or one or more halogen-substituted phenyl. A composition for suppressing SARS coronavirus contains the compound of chemical formula 1 and its pharmaceutically acceptable salt as active ingredient. Daily dose for an adult is 1mg to 1000mg once to several times a day. The composition is administered within 24 hours after coronavirus exporsrure.

    Abstract translation: 目的:提供SARS冠状病毒解旋酶和/或用于抑制SARS冠状病毒解旋酶含有芳基二酮酸(ADK)的组合物,以抑制SARS冠状病毒解旋酶的DNA双链释放。 构成:SARS冠状病毒解旋酶的DNA双链解离抑制剂含有化学式1化合物及其药学上可接受的盐。 在化学式1中,R 1是氢,R 2 -R 5独立地是氢,或者是R6-(CH2)n-R7,R6是O或NH,n是1-3的整数,并且R7是苯基或一个或多个卤素取代的 苯基。 用于抑制SARS冠状病毒的组合物含有化学式1的化合物及其药学上可接受的盐作为活性成分。 成人每日剂量为1mg至1000mg,每日一次至数次。 组合物在冠状病毒释放后24小时内给药。

    항암 효과를 갖는 불포화 케톤 및 그 유도체의 제조 방법
    9.
    发明公开
    항암 효과를 갖는 불포화 케톤 및 그 유도체의 제조 방법 失效
    制备不饱和酮及其衍生物的方法

    公开(公告)号:KR1020080024851A

    公开(公告)日:2008-03-19

    申请号:KR1020060089535

    申请日:2006-09-15

    Abstract: A method for preparing an unsaturated ketone and derivatives thereof having an anticancer effect is provided to realize a high reaction rate by using a hydrophilic solvent, to allow selective and effective introduction of different substituents, and to enable mass production of target compounds. A method for preparing an unsaturated ketone compound and derivatives thereof having and anticancer effect and represented by the following formula 1, comprises the steps of: (1) providing hydroxyethyl methylvinyl ketone represented by the following formula 3 from methyl vinyl ketone and acetaldehyde through Baylis-Hillman mechanism; and (2) converting the resultant secondary alcohol(formula 3) into an acetate compound(formula 4), and carrying out 1,4-addition of phenyl Grignard reagent in the presence of copper iodide to obtain (E)-3-benzyl-3-penten-2-one(formula 2) as a main intermediate for the target compound.

    Abstract translation: 提供了制备具有抗癌作用的不饱和酮及其衍生物的方法,以通过使用亲水性溶剂实现高反应速率,允许选择性和有效地引入不同的取代基,并且能够大规模生产目标化合物。 由下式1表示的具有抗癌作用的不饱和酮化合物及其衍生物的制备方法包括以下步骤:(1)由甲基乙烯基酮和乙醛通过Baylis- 希尔曼机制 和(2)将所得仲醇(式3)转化成乙酸酯化合物(式4),并在碘化铜存在下进行苯基格氏试剂的1,4-加成,得到(E)-3-苄基 - 3-戊烯-2-酮(式2)作为目标化合物的主要中间体。

Patent Agency Ranking